Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.54 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17413763 | 0.98 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1PPARDCYSLTR2 | |
| SCHEMBL25175611 | 0.94 | FFAR1 (0.76) | FFAR1FFAR4KEAP1CYSLTR2CYSLTR1 | |
| SCHEMBL17345292 | 0.88 | PPARA (0.69) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL25456542 | 0.88 | PPARA (0.69) | FFAR1CYSLTR2CYSLTR1 | |
| SCHEMBL1206101 | 0.88 | PPARA (0.64) | FFAR1 | |
| SCHEMBL947863 | 0.88 | FFAR1 (0.67) | FFAR1CYSLTR2CYSLTR1S1PR1 | |
| SCHEMBL1206748 | 0.86 | LMNA (0.68) | FFAR1FFAR4PPARD | |
| SCHEMBL2772855 | 0.86 | FFAR1 (0.83) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL4530820 | 0.85 | FFAR1 (0.88) | FFAR1FFAR4PPARDS1PR1 | |
| SCHEMBL1746650 | 0.85 | FFAR1 (0.88) | FFAR1FFAR4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| WO-2016002948-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | 国立大学法人東京大学 | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | LPAR3, LPAR1, LPAR4 | FFAR1 84/4885FFAR4 80/4885AKR1B1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.